Genprex Retains Addison Whitney for Drug Nomenclature Branding
May 08 2019 - 8:30AM
Business Wire
Genprex takes next steps toward identifying
drug name for future commercialization
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company, today announced that it has taken a significant step
toward commercialization of its lead drug candidate by retaining
the services of leading pharmaceutical branding agency, Addison
Whitney. Addison Whitney, a Syneos Health company, will draw from
its 28-year history to oversee the proprietary and non-proprietary
drug naming process for Genprex’s lead drug candidate, currently
known as Oncoprex™ immunogene therapy, for non-small cell lung
cancer. Oncoprex immunogene therapy has shown promise in targeting
and treating non-small cell lung cancer (NCSLC) through its
proprietary technology platform, which transports cancer-fighting
genes to cancerous cells by encapsulating the genes into nanoscale
hollow spheres, called nanovesicles, which are then administered
intravenously.
Addison Whitney has a proven track record of helping
pharmaceutical companies achieve growth through brand
differentiation and creative naming practices, most recently
leading well-known drugs such as Harvoni and Letairis through the
regulatory naming approval process.
“At Addison Whitney, our guiding principle is to work with
companies who are making great advances in medicine to bring
solutions to those who need them most,” said Joe Daley, Addison
Whitney’s President. “We believe Genprex is doing just that, and we
couldn’t be more excited to work with them.”
“Retaining Addison Whitney is an important step in bringing our
drug candidate to market,” said Genprex’s Chairman and CEO, Rodney
Varner. “Obtaining regulatory approval of proprietary and
non-proprietary drug names is a necessary step in securing
marketing approval, and Addison Whitney has an impressive track
record in obtaining such name approvals.”
Genprex is conducting a Phase I/II clinical trial of drug
candidate Oncoprex in combination with erlotinib against non-small
cell lung cancer at a major academic cancer center in Houston,
Texas. The company is also conducting preclinical studies to
evaluate Oncoprex in combination with immunotherapies at the same
cancer center.
The American Cancer Society estimates that more than 140,000
people die from lung cancer in the United States each year, which
is more than the number of people who die annually from colon,
breast and prostate cancers combined. NSCLC is the most common form
of lung cancer globally, representing 80 percent of lung cancer
diagnoses worldwide, and research shows that the five-year survival
rate for late stage NSCLC is less than 5%. Genprex is working to
bridge a critical gap in lung cancer treatment by combining its
immunogene therapies with approved targeted therapies and
immunotherapies to provide treatments to large patient populations
who would not otherwise be candidates for those approved drugs, or
who receive those drugs for some period and then become resistant
to them.
About Addison Whitney
Addison Whitney, a Syneos Health company, is a global leader in
pharmaceutical and healthcare brand development, creating hundreds
of strong, long-lasting brands in collaboration with established
and emerging companies. For nearly 30 years we’ve helped our
clients capture marketplace opportunities and establish sustained
differentiation through creative naming, imaginative design,
comprehensive brand strategy and insightful market research.
Headquartered in Charlotte, N.C., Addison Whitney has offices in
New York, Chicago, San Francisco, Seattle, London, Munich and
Tokyo. For more information, visit addisonwhitney.com.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook at
facebook.com/genprexinc, and LinkedIn at linkedin.com/company/genprex.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex, or Oncoprex in combination with targeted
therapies or immunotherapies, on cancer. Risks and uncertainties
associated with Genprex and its lead product candidate Oncoprex are
described more fully under the caption "Risk Factors" and elsewhere
in our filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. We undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190508005188/en/
Genprex, Inc.(877) 774-GNPX (4679)Investor
RelationsGNPX Investor Relations(877) 774-GNPX (4679) ext.
#2investors@genprex.comMedia ContactGenprex Media
RelationsKalyn Dabbs(877) 774-GNPX (4679) ext.
#3media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024